Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q1

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Moderna and GSK advance coronavirus vaccine candidates

Developments come amid rapidly growing cases across the globe

- PMLiVE

Researchers discover new antibiotic using AI

First antibiotic to be discovered using this method

dengue fever mosquito

NIH starts first trial of an antibody for malaria prevention

Results should be available in the first quarter of next year

- PMLiVE

GSK files anti-BCMA drug for myeloma after second trial win

Important drug for GSK as it rebuilds R&D pipeline

- PMLiVE

Novartis strengthens case for its combination asthma drug

Demonstrated significant benefits in uncontrolled asthma patients

- PMLiVE

Shionogi scores FDA approval for new cUTI antibiotic

Pivotal new treatment for adults with complicated urinary tract infection

- PMLiVE

GSK boosts outlook thanks to strong respiratory and vaccine sales

Key Q3 drivers include Shingrix vaccine and asthma drug Nucala

- PMLiVE

GSK takes new-class antibiotic into phase 3 for serious infections

Could provide a much-needed option for treatment-resistant infections

- PMLiVE

GSK gets FDA okay for wider use of PARP drug Zejula

New approval should help it gain some ground from AZ's rival Lynparza

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links